All News | RheumNow

All News

ICYMI: What to do about pre-clinical RA?

Save

d Robert Chao, MD

May 01, 2023

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.

Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?

Read Article

pneumocystis,PJP

PJP Prophylaxis Needed with Steroids and Rituximab

Save

d Jack Cush, MD

May 01, 2023

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Read Article

RheumNow Podcast square

National Population Insights (4.28.2023)

Save

d Jack Cush, MD

Apr 28, 2023

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article

map world global journey international

Romania to U.S.: My Journey to a Permanent Residency

Save

d Maria I. Danila, MD, MSc, MSPH

Apr 27, 2023

One in four practicing physicians in the United States are international medical graduates. I am one of them. Here is what I learned, and my advice to others who are on a similar journey.

Read Article

Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development: - Obinutuzumab - Dapirolizumab - Deucravacitinib - Litifilimab - Atacicept - Telitacicept https://t.co/jMLlRZuK6e https://t.co/8K0dYLieAH

Links:

https://bit.ly/40PMku0

Dr. John Cush RheumNow ( View Tweet)

May 01, 2023

UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

https://bit.ly/42dzSoM

Dr. John Cush RheumNow ( View Tweet)

May 01, 2023

Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

https://bit.ly/3oRO9t3

Dr. John Cush RheumNow ( View Tweet)

Apr 30, 2023

RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/0xzTobgmIQ https://t.co/YvEUMsqLyV

Links:

https://bit.ly/3n8HLNF

Dr. John Cush RheumNow ( View Tweet)

Apr 30, 2023

25 Great Women in Rheumatology This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? I'm sharing the responses. https://t.co/N1zqs3TJuv https://t.co/LXDxnXUaG9

Links:

https://bit.ly/3oYihTm

Dr. John Cush RheumNow ( View Tweet)

Apr 30, 2023

Denosumab Reduces Type II Diabetes Risk The British Medical Journal has published a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of NIDDM compared with those taking oral bisphosphonates for osteoporosis. https://t.co/7SMjp258gX https://t.co/SAUmahwV9J

Links:

https://bit.ly/41FE9BD

Dr. John Cush RheumNow ( View Tweet)

Apr 29, 2023

How Being a Patient Taught Me to Be a Better Doctor Dr. Marcella Ferrada ( @maferradastrong ) shares her experience having a rare disease and how it positively impacted her skills as a physician. https://t.co/eUHzPTjRv8 https://t.co/rTIfyLwVLY

Links:

https://bit.ly/40QMZuW

Dr. John Cush RheumNow ( View Tweet)

Apr 29, 2023

A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu

Links:

https://bit.ly/3ViOvVD

Dr. John Cush RheumNow ( View Tweet)

Apr 29, 2023

RheumThoughts: No is a complete sentence Dr. Rachel Tate ( @uptoTate ) shares her POV. https://t.co/TGcFuGl4Lp https://t.co/N0bItVkHjM

Links:

https://bit.ly/3ACBHjC

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

25 Great Women in Rheumatology This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? I'm sharing the responses. https://t.co/0d7SkgpcN5 https://t.co/nQVfs5oMFL

Links:

https://bit.ly/3L7CQo0

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

Narrative Medicine Dr. Aviya Lanis shares with us how narrative medicine helped her become a more engaging doctor. https://t.co/YJdsa50FBF https://t.co/7D3DiBnqaK

Links:

https://bit.ly/40LDJIG

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

Metanalysis of Steroids in hosp community-acquired pneumonia (CAP). 18 studies 4661 pts. Corticosteroids reduced mortality in more severe CAP (RR 0.62; 0.45 to 0.85), but not less severe CAP(RR 1.08). Steroids lower need for mech ventilation, ICU https://t.co/dj7zABqQ3r https://t.co/Mb4g7ICdX9

Links:

https://bit.ly/3Vf6f47

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

Metanalysis of IV NA Thiosulphate for Calciphylaxis in CKD shows NO improvement in skin lesion (RR 1.23; 0.85-1.78) or survival (HR 0.82; 0.57-1.18); based on 19 studies and 422 pts https://t.co/0uyHhWJpFJ https://t.co/dkRgRjh2cH

Links:

https://bit.ly/424Djy9

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/PYsTGnejOF https://t.co/AqOiiZm3uI

Links:

https://bit.ly/3LigDU6

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

NIH generated FDA approved drug costs ~$1.4-1.7 billlion for each 1st-in-class drug (vs estimated pharma industry cost of $1.5 billion per approved Rx). Govt may serve as early investor in pharma innovations. ~1/2 total R&D investment comes from US govt https://t.co/PORuiowRBy? https://t.co/urPkqX98A6

Links:

https://bit.ly/3oF6SYA

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

Prospective study.of 370 #FM pts (79% F; age 34yrs), and 79% were female w/ 14.3 tender points. A delay in Dx was signif correlated wtih Sx Severity Scale (r = 0.14) & tender points (r = 0.16), but not widespread pain. Early Dx = less severe FM. https://t.co/tvl0rkREHe https://t.co/OduJ3cq4Jg

Links:

https://bit.ly/41WaFPI

Dr. John Cush RheumNow ( View Tweet)

Apr 28, 2023

×